- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00528424
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
A Phase 3, Open-Label Extension Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease
Study AUX-CC-858 was an open-label continuation of the double-blind Study AUX-CC-857 (NCT00528606). Subjects who complete the Day 90 visit after their initial injection in Study AUX-CC-857 (NCT00528606) entered into Study AUX-CC-858. Subjects who required further treatment in Study AUX-CC-858, either because their treated metacarpophalangeal and/or proximal interphalangeal (PIP) joints did not have a reduction in contracture to 5° or less, the cord affecting that joint received less than three injections of AA4500, or they had other eligible cords that received no treatment in AUX-CC-857 (NCT00528606), had the option to receive up to five injections of AA4500 in this extension study. Subjects requiring further treatment were followed for efficacy and safety on Days 1, 7, and 30 after each injection, with injections separated by four weeks. Follow-up visits for the determination of efficacy and safety were conducted on Day 90, Month 6, and Month 9.
This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90095
- 100 UCLA Medical Plaza, Suite 305
-
Palo Alto, California, Vereinigte Staaten, 94304
- Hand Surgery Clinic
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80210
- Hand Surgery Associates, PC
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- The Hand and Upper Extremity Center of Georgia, P.C.
-
-
Illinois
-
Rockford, Illinois, Vereinigte Staaten, 61107
- Rockford Orthopedic Associates, Ltd.
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46260
- The Indiana Hand Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham and Women's Hospital, Department of Orthopedic Surgery
-
Newton, Massachusetts, Vereinigte Staaten, 02462
- Newton-Wellesley Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55431
- TRIA Orthopaedic Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Hospital For Special Surgery
-
Stony Brook, New York, Vereinigte Staaten, 11794
- SUNY Stony Brook - Department of Orthopedics
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73109
- Health Research Institute
-
-
Pennsylvania
-
Erie, Pennsylvania, Vereinigte Staaten, 16550
- Hand Microsurgery & Reconstructive Orthopaedics
-
State College, Pennsylvania, Vereinigte Staaten, 16801
- University Orthopedics Center
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02905
- Department of Orthopaedics, Brown University, Rhode Island Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.
- Had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
- Were naïve to AA4500 treatment or had received only one or two injections of AA4500 for the treatment of advanced Dupuytren's disease in AUX-CC-857 ((NCT00528606).
- Were judged to be in good health.
- Must have participated in protocol AUX-CC-857 (NCT00528606).
Exclusion Criteria:
- Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.
- Had received treatment for advanced Dupuytren's disease within 90 days of enrollment on the joint selected for the initial injection of AA4500, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon.
- Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: AA4500 0,58 mg
|
Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days.
Individual cords may have received up to a maximum of three AA4500 injections.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Reduction in Contracture to 5° or Less
Zeitfenster: Within 30 days after last injection
|
Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
|
Within 30 days after last injection
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Clinical Improvement After the Last Injection
Zeitfenster: Baseline, within 30 days after last injection
|
Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
|
Baseline, within 30 days after last injection
|
Percent Reduction From Baseline Contracture After the Last Injection
Zeitfenster: Baseline, Day 30 after last injection
|
Percent change in degree of contracture in non-primary joints measured as 100 * (baseline contracture - last available post-injection contracture)/baseline contracture.
|
Baseline, Day 30 after last injection
|
Change From Baseline Range of Motion After the Last Injection
Zeitfenster: Baseline, Day 30 after last injection
|
Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion
|
Baseline, Day 30 after last injection
|
Time to Reach Clinical Success
Zeitfenster: Within 30 days after last injection
|
Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories
|
Within 30 days after last injection
|
Clinical Success After the First Injection
Zeitfenster: Within 30 days after first injection
|
Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
|
Within 30 days after first injection
|
Clinical Improvement After the First Injection
Zeitfenster: Baseline, within 30 days after first injection
|
Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
|
Baseline, within 30 days after first injection
|
Percent Reduction From Baseline Contracture After the First Injection
Zeitfenster: Baseline, Day 30 after first injection
|
Percent change in degree of contracture in non-primary joints measured as 100 * (baseline contracture - last available post-injection contracture)/baseline contracture.
|
Baseline, Day 30 after first injection
|
Change From Baseline Range of Motion After the First Injection
Zeitfenster: Baseline, Day 30 after first injection
|
Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion
|
Baseline, Day 30 after first injection
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Veronica Urdaneta, MD, Endo Pharmaceuticals
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- AUX-CC-858
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Fortgeschrittener Morbus Dupuytren
-
National University of SingaporeCalifornia Table Grape CommissionNoch keine RekrutierungAltern | Makula; Degeneration | Advanced Glycation End-Produkte
-
Extremity MedicalRekrutierungArthrose | Entzündliche Arthritis | Karpaltunnelsyndrom (CTS) | Posttraumatische Arthritis | Scapholunate Advanced Collapse (SLAC) | Scapholunate Crystalline Advanced Collapse (SCAC) | Scaphoid, Trapezium und Trapezoid Advanced Collapse (STTAC) | Kienbock-Krankheit des Erwachsenen | Radiale Malunion | Ulnare Translokation und andere BedingungenVereinigte Staaten
-
Northwell HealthZurückgezogenDiabetes | SGLT-2-Inhibitoren | Advanced Glycation End-Produkte
-
Töölö HospitalTurku University Hospital; Tampere University Hospital; Jyväskylä Central Hospital und andere MitarbeiterRekrutierungArthrose am Handgelenk | Scapholunate Advanced CollapseFinnland
-
Advanced BionicsAbgeschlossenSchwerer bis hochgradiger Hörverlust | bei erwachsenen Benutzern des Advanced Bionics HiResolution™ Bionic Ear SystemVereinigte Staaten
-
University of AlbertaArthritis Society Canada; Wrist Evaluation Canada (WECAN)RekrutierungArthritis | Gelenkerkrankungen | Erkrankungen des Bewegungsapparates | Posttraumatisch; Arthrose | Arthrose am Handgelenk | Kahnbein-Pseudarthrose | Scapholunate Advanced Collapse | Arthropathie am HandgelenkKanada
-
The Leeds Teaching Hospitals NHS TrustAktiv, nicht rekrutierendWunden und Verletzungen | Chirurgie | Rehabilitation | Orthopädische Störung | Vom Patienten gemeldete Ergebnismessungen | Bewertung der Behinderung | Wiederherstellung der Funktion | Mehrere Traumata/Verletzungen | Traumazentren | Trauma-Schwere-Indizes | Advanced Trauma Life Support CareVereinigtes Königreich
-
Maastricht University Medical CenterAbgeschlossenDiät | Gefäßfunktion | Insulinsensitivität/-resistenz | Beta-Zell-Funktion | Advanced Glycation End-Produkte | ALTERNiederlande
-
TakedaAktiv, nicht rekrutierendALK+ Advanced NSCLCSpanien, China, Korea, Republik von, Taiwan, Hongkong, Thailand, Italien, Rumänien, Vereinigte Staaten, Mexiko, Kroatien, Russische Föderation, Argentinien, Kanada, Deutschland, Frankreich, Österreich, Chile, Griechenland, Sch...
-
QIAGEN Gaithersburg, IncAbgeschlossenRespiratory-Syncytial-Virus-Infektionen | Grippe A | Rhinovirus | Influenza B | QIAGEN ResPlex II Advanced Panel | Infektion durch das humane Parainfluenzavirus 1 | Parainfluenza Typ 2 | Parainfluenza Typ 3 | Parainfluenza Typ 4 | Humanes Metapneumovirus A/B | Coxsackie-Virus/Echovirus | Adenovirus-Typen B... und andere BedingungenVereinigte Staaten
Klinische Studien zur AA4500
-
Endo PharmaceuticalsAbgeschlossenPeyronie-KrankheitVereinigte Staaten
-
Endo PharmaceuticalsAbgeschlossenPeyronie-KrankheitVereinigte Staaten, Dänemark, Frankreich, Deutschland, Italien, Neuseeland, Spanien, Schweden, Vereinigtes Königreich
-
Endo PharmaceuticalsAbgeschlossenPeyronie-KrankheitVereinigte Staaten, Australien
-
Endo PharmaceuticalsAbgeschlossenPeyronie-KrankheitVereinigte Staaten, Australien
-
Endo PharmaceuticalsAbgeschlossenA Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's ContractureDupuytren-KontrakturVereinigte Staaten
-
Endo PharmaceuticalsAbgeschlossen
-
Endo PharmaceuticalsAbgeschlossenPeyronie-KrankheitVereinigte Staaten
-
Endo PharmaceuticalsAbgeschlossen
-
Endo PharmaceuticalsAbgeschlossenFortgeschrittener Morbus DupuytrenVereinigte Staaten
-
Gerut, Zachary, M.D.Advance Biofactures CorporationAbgeschlossen